ArriVent BioPharma

About ArriVent BioPharma

ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated medicines for unmet medical needs, particularly in difficult-to-treat diseases like cancer. Their mission is to maximize the potential of their lead candidate, firmonertinib, and advance a pipeline of novel oncology therapeutics through strategic collaborations and regulatory strategies.

Products & Services

Firmonertinib:A lead development candidate (previously known as furmonertinib) aimed at addressing unmet needs in cancer treatment, currently in clinical trials.

Oncology Therapeutics Pipeline:Includes novel therapies such as next-generation antibody drug conjugates, under development for cancer treatment.

Specialties

Oncology Drug Development Clinical Trials Regulatory Strategy Strategic Collaborations

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering of Common Stock and Pre-Funded Warrants T: - FT: Public Offering of Common Stock and Pre-Funded Warrants	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2025-07-01 FD: 2025-07-01	3 investors
2	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2025-07-01 FD: 2025-07-01	8 investors
3	RT: Initial Public Offering (IPO) T: - FT: Initial Public Offering (IPO)	A: 175000000 MR: - FA: $175.0 million FAN: 175000000	D: 2024-01-25 FD: 2024-01-25	4 investors
4	RT: Series B T: - FT: Series B	A: 155000000 MR: - FA: 155 million FAN: 155000000	D: 2023-03-27 FD: 2023-03-27	15 investors

Public Offering of Common Stock and Pre-Funded Warrants Latest

2025-07-01

$75.0M

3 investors (Pro only)

Public Offering 2025-07-01

$75.0M

Initial Public Offering (IPO) 2024-01-25

$175.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Z

Zhengbin (Bing) Yao

Chief Executive Officer

S

Stuart Lutzker

President, R&D

R

Robin LaChapelle

Chief Operating Officer

W

Winston Kung

Chief Financial Officer

Y

Yang Wang

Chief Technology Officer

J

James Kastenmayer

General Counsel

View 9 more team members with Pro

Unlock Full Team Directory

Recent News